Aurobindo Pharma Limited, is pleased to announce the audited financial results for the year ended 31st March 2008.

The highlights are as under:
_ Financials Consolidated:
• Total Income up by 16.5% to Rs 2530Crs (Rs 2172 Crs)
• PBT up by 41.3% to Rs 291.75 Crs (Rs 206.42 Crs)
• PAT up by 18.7% to Rs 238.48 Crs (Rs 200.96 Crs)
• Gross Margin improves to 44.50% from 42.45%
• Net Margin improves to 9.43% from 9.25%
• Formulation Sales up by 44.81% to Rs 1005 Crs (Rs 694 Crs)
* Pen-G price continue to be stable, China operations stabilize
* 46 ANDA filings in USA in FY 2007-08, cumulative filings 128
* Despite pressure in generic prices. US sales clock USD 59 mn (USD 39 mn) &
* Europe sales USD 50 mn (USD 32 mn)
* Overall borrowings decline to Rs 1847 Crs from Rs 2078 Crs

Consolidated 2007-08

The Company has registered a total income of Rs.2530 crores (Rs.2172 crores) up by 16.5%.The profit before tax has jumped to Rs.292 crores (Rs.206 crores) up by 41.7%. After making a provision for tax of Rs.54 crores (Rs.4 crores) the net profit stands at Rs.238 crores (Rs.201 crores) up by 18.4%.

The consolidated EBIDTA stands at Rs.435 crores (Rs.351 crores) up by 23.9%.

Standalone 2007-08

The Company has registered a total income of Rs.2353 crores (Rs.1918 crores) up by 22.7%. The profit before tax has jumped to Rs.345 crores (Rs.231 crores) up by 49.3%. After making a provision for tax of Rs.54 crores (Rs.2 crores) the net profit stands at Rs.291 crores (Rs.229 crores) up by 27.1%.

The standalone EBIDTA stands Rs.435 crores (Rs.321 crores) up by 35.5%.

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Aurobindo Pharma’s total income Rs 549.42cr
• Rel Capital reports cons net profit of Rs 1009cr
• CRISIL reports cons total income of Rs 413.49cr, up 40.63%
• Zicom’s net PAT of Rs 8.04cr
• Orchid’s total income up by 29.6% to Rs 306.33cr